Apoptosis in glomerulonephritis

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 4, 2005, Pages 389-395

  Hughes, Jeremy ^a   Savill, John S ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Apoptosis; Glomerulonephritis; Inflammation

Indexed keywords

CASPASE INHIBITOR; COLLAGEN; EPIDERMAL GROWTH FACTOR; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; REAGENT; RECOMBINANT GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

APOPTOSIS; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; CHRONIC INFLAMMATION; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; INFLAMMATION; PHAGOCYTOSIS; PODOCYTE; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

EID: 20844437067     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000172728.82993.4e     Document Type: Review

References (69)

1. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257.
2. Savill J. Macrophage recognition of senescent neutrophils. Clin Sci 1992; 83:649-655.
3. Hughes J, Liu Y, Van Damme J, Savill J. Human glomerular mesangial cell phagocytosis of apoptotic neutrophils: mediation by a novel CD36-independent vitronectin receptor/thrombospondin recognition mechanism that is uncoupled from chemokine secretion. J Immunol 1997; 158:4389-4397.
4. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2:965-975.
5. Tashiro K, Kodera S, Takahashi Y, et al. Detection of apoptotic cells in glomeruli of patients with IgA nephropathy. Nephron 1998; 79:21-27.
6. Makino H, Sugiyama H, Yamasaki Y, et al. Glomerular cell apoptosis in human lupus nephritis. Virchows Arch 2003; 443:67-77.
7. Baker AJ, Mooney A, Hughes J, et al. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994; 94:2105-2116.
8. Shankland SJ. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation and apoptosis. Am J Physiol Renal Physiol 2000; 278:F515-F529.
9. Mooney A, Jobson T, Bacon R, et al. Cytokines promote glomerular mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis. J Immunol 1997; 159:3949-3960.
10. Sugiyama H, Savill JS, Kitamura M, et al. Selective sensitization to tumor necrosis factor-alpha-induced apoptosis by blockade of NF-kappaB in primary glomerular mesangial cells. J Biol Chem 1999; 274:19532-19537.
11. Duffield JS, Ware CF, Ryffel B, Savill J. Suppression by apoptotic cells defines tumor necrosis factor-mediated induction of glomerular mesangial cell apoptosis by activated macrophages. Am J Pathol 2001; 159:1397-1404.
12. Maruyama K, Kashihara N, Yamasaki Y, et al. Methylprednisolone accelerates the resolution of glomerulonephritis by sensitizing mesangial cells to apoptosis. Exp Nephrol 2001; 9:317-326.
13. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15:2115-2124. There is a body of data in the neurological literature indicating that erythropoietin can protect neurones from a variety of proapoptotic stimuli in vitro and in vivo and this work is now being extended to the renal field. This study demonstrates that recombinant erythropoietin protects human proximal tubular cells from undergoing apoptosis in vitro and ameliorates renal injury in a model of murine ischaemia-reperfusion injury.
14. Westenfelder C. Unexpected renal actions of erythropoietin. Exp Nephrol 2002; 10:294-298.
15. Fishbane S, Ragolia L, Palaia T, et al. Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 2004; 65:452-458. Recombinant EPO protects LLC-PK1 tubular cells and murine mesangial cells from undergoing apoptosis in vitro.
16. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16:307-312.
17. Wornle M, Schmid H, Merkle M, Banas B. Effects of chemokines on proliferation and apoptosis of human mesangial cells. BMC Nephrol 2004; 5:8. The chemokine SLC/CCL21 protects human mesangial cells from Fas-mediated apoptosis, although other chemokines tested have variable effects.
18. Makino H, Sugiyama H, Kashihara N. Apoptosis and extracellular matrix-cell interactions in kidney disease. Kidney Int 2000; 58 (Suppl 77):67-75.
19. Mooney A, Jackson K, Bacon R, et al. Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via beta(1) integrin-mediated survival signals. Am J Pathol 1999; 155:599-606.
20. Kochlatyi S, Gibbons N, Mattana J. Extracellular matrix oxidation modulates survival, NF-kappaB translocation, and MAPK activity in mesangial cells. Exp Mol Pathol 2002; 73:191-197.
21. Daha MR. Mechanisms of mesangial injury in glomerular diseases. J Nephrol 2000; 13 (Suppl 3):S89-S95.
22. Takemura T, Murakami K, Miyazato H, et al. Expression of Fas antigen and Bcl-2 in human glomerulonephritis. Kidney Int 1995; 48:1886-1892.
23. Badillo-Almaraz I, Daza L, Avalos-Dias E, et al. Glomerular expression of Fas ligand and Bax mRNA in lupus nephritis. Autoimmunity 2001; 34:283-289.
24. Tsukinoki T, Sugiyama H, Sunami R, et al. Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells. Clin Exp Nephrol 2004; 8:196-205. Mesangial cell FasL is upregulated in a series of human renal biopsies from patients with lupus nephritis and cytokines upregulate human mesangial cell FasL expression in vitro via the transcription factor NF-κB.
25. Kluth DC, Erwig L-P, Rees AJ. Multiple facets of macrophages in renal injury. Kidney Int 2004; 66:542-557. An excellent and comprehensive overview of the role of macrophages in renal inflammation.
26. Duffield JS, Erwig L-P, Wei X, et al. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells. J Immunol 2000; 164:2110-2119.
27. Wang JS, Tseng HH, Shih DF, et al. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 1997; 77:404-411.
28. Cattell V. Nitric oxide and glomerulonephritis. Semin Nephrol 1999; 19:277-287.
29. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003; 23:1553-1558.
30. Boyle JJ, Weissberg PL, Bennett MR. Human macrophage-induced vascular smooth muscle cell apoptosis requires NO enhancement of Fas/Fas-L interactions. Arterioscler Thromb Vasc Biol 2002; 22:1624-1630.
31. Boyle JJ. Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16. Clin Exp Immunol 2004; 137:529-537. In-vitro studies demonstrating that antibody-coated mesangial cells are vulnerable to macrophage-mediated apoptosis.
32. Bijan K, Takano T, Papillon J, et al. Extracellular matrix regulates glomerular epithelial cell survival and proliferation. Am J Physiol Renal Physiol 2004; 286:F255-F266. These studies demonstrated the key role of integrin-mediated binding to ECM in podocyte survival.
33. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285:F40-F48.
34. Floege J, Kriz W, Schulze M, et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 1995; 96:2809-2819.
35. Fornoni A, Li H, Foschi A, et al. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am J Pathol 2001; 158:275-280.
36. Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65:30-39. Mechanical stretch induces significant angiotensin II-mediated podocyte apoptosis in vitro via increased angiotensin II production and upregulation of the angiotensin II type 1 receptor.
37. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108:807-816.
38. Ortmann J, Amann K, Brandes RP, et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44:974-981. In-vitro studies indicated that inhibition of endothelin protects podocytes from undergoing apoptosis following treatment with puromycin. Also, prolonged administration of an endothelin receptor antagonist inhibited spontaneous age-related glomerulosclerosis in a rat model.
39. Schiffer M, Mundel P, Shaw AS, Bottinger EP. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 2004; 279:37004-37012. This study extends the role of CD2-associated protein in podocytes by demonstrating an antiapoptotic function.
40. Foster RR, Hole R, Anderson K, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284:F1263-F1273.
41. Foster RR, Saleem MA, Mathieson PW, et al. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2005; 288:F48-F57. This in-vitro work dissects the mechanism underlying the antiapoptotic effect of VEGF on podocytes and demonstrates a role for phosphorylation of nephrin following VEGF stimulation.
42. Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, et al. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol 2003; 139:823-831.
43. Qiu LQ, Sinniah R, I-Hong Hsu S. Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human IgA nephropathy. J Am Soc Nephrol 2004; 15:79-90.
44. Shimizu A, Kitamura H, Masuda Y, et al. Glomerular capillary regeneration and endothelial cell apoptosis in both reversible and progressive models of glomerulonephritis. Contrib Nephrol 1996; 118:29-40.
45. Woywodt A, Streiber F, de Groot K, et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003; 61:206-210.
46. Lang RA, Bishop JM. Macrophages are required for cell death and tissue remodeling in the developing mouse eye. Cell 1993; 74:453-462.
47. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model. II: Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12:1448-1457.
48. Miyamoto K, Kitamoto Y, Tokunaga H, et al. Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat. Lab Invest 2004; 84:1126-1136. Administration of exogenous VEGF is protective in a mild model of Thy 1.1. glomerulonephritis, although no effect upon endothelial cell apoptosis is evident.
49. Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl 1998; 65:374-378.
50. Messmer UK, Winkel G, Briner VA, Pfeilschifter J. Suppression of apoptosis by glucocorticoids in glomerular endothelial cells: effects on proapoptotic pathways. Br J Pharmacol 2000; 129:1673-1683.
51. Savill J. Apoptosis in disease. Eur J Clin Invest 1994; 24:715-723.
52. Savill J, Smith J, Sarraf C, et al. Glomerular mesangial cells and inflammatory macrophages ingest neutrophils undergoing apoptosis. Kidney Int 1992; 42:924-936.
53. Hughes J, Johnson RJ, Mooney A, et al. Neutrophil fate in experimental glomerular capillary injury in the rat: emigration exceeds in situ clearance by apoptosis. Am J Pathol 1997; 150:223-234.
54. Ren Y, Savill J. Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. J Clin Invest 1995; 154:2366-2374.
55. Liu Y, Cousin JM, Hughes J, et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 1999; 162:3639-3646.
56. Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 1999; 162:480-485.
57. Lan HY, Nikolic-Paterson DJ, Atkins RC. Trafficking of inflammatory macrophages from the kidney to draining lymph nodes during experimental glomerulonephritis. Clin Exp Immunol 1993; 92:336-341.
58. Lan HY, Mitsuhashi H, Ng YY, et al. Macrophage apoptosis in rat crescentic glomerulonephritis. Am J Pathol 1997; 151:531-538.
59. Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19:56-59.
60. Mitchell DA, Taylor PR, Cook HT, et al. Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol 1999; 162:5676-5679.
61. Robson MG, Cook HT, Botto M, et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001; 166(11):6820-6828.
62. Gillmore JD, Hutchinson WL, Herbert J, et al. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? Immunology 2004; 112:255-264. This study reinforces the importance of the background genetic strain of mice when analysing the phenotype of genetically modified mice. The serum amyloid P knockout mouse exhibits an autoimmune phenotype that varies with the background genetic strain.
63. Ren Y, Tang J, Mok MY, et al. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003; 48:2888-2897.
64. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199:265-285.
65. Kang DH, Kim YG, Andoh TF, et al. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am J Physiol Renal Physiol 2001; 280:F727-F736.
66. Kim YG, Suga SI, Kang DH, et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000; 58:2390-2399.
67. Yang B, Johnson TS, Haylor JL, et al. Effects of caspase inhibition on the progression of experimental glomerulonephritis. Kidney Int 2003; 63:2050-2064.
68. Seery JP, Cattell V, Watt FM. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(beta-o-methyl)- fluoromethylketone. J Immunol 2001; 167:2452-2455.
69. Chevalier RL, Goyal S, Thornhill BA. EGF improves recovery following relief of unilateral ureteral obstruction in the neonatal rat. J Urol 1999; 162:1532-1536.